ATE471371T1 - Antikrebsmittel mit verotoxinvarianten - Google Patents

Antikrebsmittel mit verotoxinvarianten

Info

Publication number
ATE471371T1
ATE471371T1 AT03703141T AT03703141T ATE471371T1 AT E471371 T1 ATE471371 T1 AT E471371T1 AT 03703141 T AT03703141 T AT 03703141T AT 03703141 T AT03703141 T AT 03703141T AT E471371 T1 ATE471371 T1 AT E471371T1
Authority
AT
Austria
Prior art keywords
verotoxin
subunit
anticancer agent
attenuated
verotoxinvariants
Prior art date
Application number
AT03703141T
Other languages
English (en)
Inventor
Xiaoyan Liu
Original Assignee
Yoshida Hideo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshida Hideo filed Critical Yoshida Hideo
Application granted granted Critical
Publication of ATE471371T1 publication Critical patent/ATE471371T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03703141T 2002-02-04 2003-02-03 Antikrebsmittel mit verotoxinvarianten ATE471371T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002026577 2002-02-04
PCT/JP2003/001043 WO2003066854A1 (fr) 2002-02-04 2003-02-03 Agent anticancereux utilisant des variantes de verotoxines

Publications (1)

Publication Number Publication Date
ATE471371T1 true ATE471371T1 (de) 2010-07-15

Family

ID=27677819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03703141T ATE471371T1 (de) 2002-02-04 2003-02-03 Antikrebsmittel mit verotoxinvarianten

Country Status (7)

Country Link
US (3) US20050163807A1 (de)
EP (1) EP1496116B1 (de)
JP (1) JP4214397B2 (de)
AT (1) ATE471371T1 (de)
AU (1) AU2003208097A1 (de)
DE (1) DE60333004D1 (de)
WO (1) WO2003066854A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
EP2207793A2 (de) * 2007-10-08 2010-07-21 Rutgers, The State University Nicht toxische shigatoxinmutanten-zusammensetzungen und entsprechende verfahren
US20120201853A1 (en) 2009-08-28 2012-08-09 Clifford Lingwood Use of a holotoxin to reduce endoplasmic reticulum-associated degradation of misfolded proteins
WO2014004838A2 (en) 2012-06-28 2014-01-03 Universal Instruments Corporation Flexible assembly machine, system and method
EP2970487B1 (de) 2013-03-12 2020-03-11 Molecular Templates, Inc. Zytotoxische proteine mit zellgerichteten bindungsregionen und shigatoxin-a-untereinheitsregionen zur selektiven tötung von spezifischen zellarten
KR20160113158A (ko) 2014-01-27 2016-09-28 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
JP6678596B2 (ja) 2014-02-07 2020-04-08 ユニヴァーサル インストゥルメンツ コーポレイションＵｎｉｖｅｒｓａｌ Ｉｎｓｔｒｕｍｅｎｔｓ Ｃｏｒｐｏｒａｔｉｏｎ ポンプとモーターを持つピックアンドプレースヘッド
WO2015138435A1 (en) * 2014-03-11 2015-09-17 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3872090A1 (de) * 2014-03-11 2021-09-01 Molecular Templates, Inc. Proteine mit aminoterminalen proximalen shiga-toxin-a-untereinheiteneffektorregionen und gegen zellen gerichteten immunglobulinbindungsregionen
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
JP6444486B2 (ja) 2015-02-05 2018-12-26 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
MX2018001208A (es) * 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
JP7075134B2 (ja) 2016-12-07 2022-05-25 モレキュラー テンプレーツ，インク． 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
US10454114B2 (en) 2016-12-22 2019-10-22 The Research Foundation For The State University Of New York Method of producing stable, active and mass-producible Pt3Ni catalysts through preferential co etching
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
AU7348998A (en) * 1997-05-16 1998-12-08 Hospital For Sick Children, The Inhibition of angiogenesis by verotoxins

Also Published As

Publication number Publication date
HK1073130A1 (en) 2005-09-23
EP1496116A4 (de) 2005-08-24
JP4214397B2 (ja) 2009-01-28
JPWO2003066854A1 (ja) 2005-06-02
US20100047285A1 (en) 2010-02-25
DE60333004D1 (de) 2010-07-29
WO2003066854A1 (fr) 2003-08-14
AU2003208097A1 (en) 2003-09-02
US20070154485A1 (en) 2007-07-05
US20050163807A1 (en) 2005-07-28
EP1496116B1 (de) 2010-06-16
EP1496116A1 (de) 2005-01-12

Similar Documents

Publication Publication Date Title
ATE471371T1 (de) Antikrebsmittel mit verotoxinvarianten
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
DE60129695D1 (de) Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
DE60115349D1 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
ATE466079T1 (de) Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
DE60226253D1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
AU2003234342A8 (en) Ablated slam-dependent entry
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO2021034975A3 (en) Protein panels for the early diagnosis/prognosis and treatment of aggressive prostate cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties